Source Paper
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Bita Moghaddam, Barbara Adams, Anita Verma, Darron Daly
Journal of Neuroscience • 1997
Systemic LY293558 Pretreatment
Objective: To assess the effects of systemic AMPA/kainate receptor antagonist LY293558 pretreatment on ketamine-induced dopamine activation and impairment of spatial delayed alternation performance in the prefrontal cortex
This is a Systemic LY293558 Pretreatment protocol using rat as the model organism. The procedure involves 4 procedural steps, 2 equipment items, 3 materials. Extracted from a 1997 paper published in Journal of Neuroscience.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Systemic LY293558 Pretreatment • Ketamine Administration • Microdialysis Measurement
Primary readouts
- Glutamate outflow in the prefrontal cortex
- Dopamine release in the prefrontal cortex
- Performance on spatial delayed alternation task
- Blockade of ketamine-induced dopamine activation by LY293558
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Systemic LY293558 Pretreatment
Administer AMPA/kainate receptor antagonist LY293558 systemically prior to ketamine treatment
Note: Pretreatment timing relative to ketamine administration not specified
View evidence from paper
“systemic pretreatment with AMPA/kainate receptor antagonist LY293558”
Ketamine Administration
Administer ketamine at specified dose following LY293558 pretreatment
Note: Dose-response study tested 10, 20, 30, 50, and 200 mg/kg doses
View evidence from paper
“low doses of ketamine (10, 20, and 30 mg/kg) increase glutamate outflow in the PFC”
Microdialysis Measurement
Measure glutamate and dopamine outflow in the prefrontal cortex using microdialysis in conscious rats
Note: Measurements taken in conscious animals
View evidence from paper
“A thorough dose-response study using microdialysis in conscious rats indicated that low doses of ketamine”
Spatial Delayed Alternation Task
Assess cognitive performance on spatial delayed alternation, a PFC-sensitive task
Note: Task used to measure ketamine-induced cognitive impairment
View evidence from paper
“ketamine-induced activation of dopamine release and impairment of spatial delayed alternation in the rodent, a PFC-sensitive cognitive task”